Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19123381 | 0.76 | APLNR (0.33) | CHRNA7 | |
| SCHEMBL2757603 | 0.74 | APLNR (0.36) | CHRNA7 | |
| SCHEMBL3265716 | 0.74 | LMNA (0.32) | CHRNA7 | |
| SCHEMBL103916 | 0.72 | TYR (0.34) | CHRNA7 | |
| SCHEMBL19069423 | 0.72 | RXRA (0.34) | CHRNA7 | |
| SCHEMBL21500577 | 0.72 | HDAC8 (0.36) | CHRNA7 | |
| SCHEMBL84396 | 0.72 | HSP90AA1 (0.36) | CHRNA7 | |
| SCHEMBL459264 | 0.72 | NFKB1 (0.38) | CHRNA7 | |
| SCHEMBL31736867 | 0.72 | NPC1 (0.37) | CHRNA7 | |
| SCHEMBL1035897 | 0.72 | LMNA (0.34) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-11178871-B2 | Herbicidal pyrimidine compounds | BASF SE (DE) | 2021-11-23 | — | — | US | disclosed |
| WO-2021064570-A1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| EP-3490985-B1 | HERBICIDAL PYRIMIDINE COMPOUNDS | BASF SE (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190159453-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | BASF SE (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CHRNA7 3984/4885 |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | CHRNA7 3286/4885 |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CHRNA7 3984/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CHRNA7 4863/4885 |
| US-11178871-B2 | Herbicidal pyrimidine compounds | DPYD, TYMP, TYMS | CHRNA7 4395/4885 |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | CHRNA7 973/4885 |
| US-20190159453-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | DPYD, TYMP, TYMS | CHRNA7 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.